Which new diagnostics for tuberculosis, and when?

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 2, 2012, Pages

  Cobelens, Frank ^a   Van Den Hof, Susan ^a,b   Pai, Madhukar ^c   Squire, S Bertel ^d   Ramsay, Andrew ^e   Kimerling, Michael E ^f  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c MCGILL UNIVERSITY   (Canada)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL ASSESSMENT TOOL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEASIBILITY STUDY; GRADING OF RECOMMENDATIONS ASSESSMENT DEVELOPMENT AND EVALUATION PROCESS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; DEVELOPING COUNTRIES; EVALUATION STUDIES AS TOPIC; HEALTH POLICY; HUMANS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 84860372578     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis188     Document Type: Review

References (33)

1. McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis diagnostics and biomarkers: Needs, challenges, recent advances, and opportunities. J Infect Dis 2012; 205(Suppl 2):S147-58.
2. Nahid , Kim PS, Evans CA, et al. Clinical research and development of tuberculosis diagnostics: Moving from silos to synergy. J Infect Dis 2012; 205(Suppl 2):S159-68.
3. World Health Organization. Global tuberculosis control. Geneva: World Health Organization, 2011. http://www.who.int/tb/publications/global-report/en/ index.html Accessed 21 June 2011.
4. Pai M, Minion J, Steingart K, Ramsay A. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 2010; 16:271-84.
5. World Health Organization. WHO endorses new rapid tuberculosis test, 2010. http://www.who.int/tb/laboratory/new-rapid-test/en/index. html. Accessed 10 June 2011.
6. Schünemann HJ, Schünemann AH, Oxman AD, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336:1106-10.
7. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
8. Schito M, Peter TF, Cavanaugh S, et al. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J Infect Dis 2012; 205(Suppl 2):S169-80.
9. van Kampen SC, Ramsay AR, Anthony RM, Klatser PR. Retooling national TB control programmes (NTPs) with new diagnostics: the NTP perspective. PLoS One 2010; 5:e11649.
10. Mann G, Squire SB, Bissell K, et al. Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools. Int J Tuberc Lung Dis 2010; 14:1518-24.
11. Soto A, Solari L, Gotuzzo E, Acinelli R, Vargas D, Van der Stuyft P. Performance of an algorithm based on WHO recommendations for the diagnosis of smear-negative pulmonary tuberculosis in patients without HIV infection. Trop Med Int Health 2011; 16:424-30.
12. Koole O, Thai S, Khun KE, et al. Evaluation of the 2007WHOguideline to improve the diagnosis of tuberculosis in ambulatory HIV-positive adults. PLoS One 2011; 6:e18502.
13. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-505.
14. Pai M, Ramsay A, O'Brien R. Evidence-based tuberculosis diagnosis. PLoS Med 2008; 5:e156.
15. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177:787-92.
16. Squire SB, Ramsay AR, van den Hof S, et al. Making innovations accessible to the poor through implementation research. Int J Tuberc Lung Dis 2011; 15:862-70.
17. World Health Organization. Noncommercial culture and drugsusceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis: policy statement. WHO/HTM/TB/2011.9. Geneva, Switzerland: World Health Organization, 2011.
18. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011; 8:e1001120.
19. World Health Organization. TB diagnostics and laboratory strengthening. http://www.who.int/tb/laboratory/en/. Accessed 10 June 2011.
20. Stop TB Partnership's New Diagnostics Working Group, World Health Organization. Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics. Geneva: World Health Organization, 2009.
21. Lijmer JG, Leeflang M, Bossuyt PM. Proposals for a phased evaluation of medical tests. Med Decis Making 2009; 29:E13-21.
22. Ramsay A, Steingart KR, Pai M. Assessing the impact of new diagnostics on tuberculosis control. Int J Tuberc Lung Dis 2010; 14:1506-7.
23. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375:1920-37.
24. Steingart KR, Flores LL, Dendukuri N, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med 2011; 8:e1001062.
25. Dowdy DW, Steingart KR, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis. PLoS Med 2011; 8:e1001074.
26. World Health Organization. Policy statement: commercial serodiagnostic tests for diagnosis of tuberculosis. WHO/HTM/TB/2011.5. Geneva: World Health Organization, 2011. http://whqlibdoc.who.int/publications/2011/9789241502054- eng.pdf. Accessed 21 June 2011.
27. Porta MA. Dictionary of epidemiology. 5th ed. New York, NY: Oxford University Press, 2008.
28. Rusen ID, Squire SB, Billo NE. Poverty and lung health. Expert Rev Respir Med 2010; 4:163-5.
29. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009; 10:37.
30. Moulton LH, Golub JE, Durovni B, et al. Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clin Trials 2007; 4:190-9.
31. Mowatt G, Grimshaw JM, Davis DA, Mazmanian PE. Getting evidence into practice: the work of the Cochrane Effective Practice and Organization of care Group (EPOC). J Contin Educ Health Prof 2001; 21:55-60.
32. Uys PW, Warren R, van Helden PD, Murray M, Victor TC. Potential of rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in communities where Mycobacterium tuberculosis infections are highly prevalent. J Clin Microbiol 2009; 47:1484-90.
33. Roos BR, van Cleeff MR, Githui WA, et al. Cost-effectiveness of the polymerase chain reaction versus smear examination for the diagnosis of tuberculosis in Kenya: a theoretical model. Int J Tuberc Lung Dis 1998; 2:235-41.